Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eastern Cooperative Oncology Group
With
National Cancer Institute (NCI)
OBJECTIVES:
* To identify mutations in oncogenes and tumor suppressors of peripheral T-cell lymphoma or natural killer (NK) cell neoplasm.
* To delineate the mechanisms that mediate oncogenic effects and their clinical prognostic significance in these diseases.
* To perform a comprehensive mutation analysis via whole exome resequencing in a panel of peripheral T-cell or NK lymphomas.
OUTLINE: Fixed paraffin-embedded tumor tissue samples are analyzed for mutations by the Illumina HiSeq platform. Sequencing reads are performed by GAPipeline version 1.5.1 and mapping on the human genome performed using the MAQ software version 0.7.1. Genes harboring validated somatic mutations are then amplified by PCR and analyzed by Sanger resequencing.
Age
18–120
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Diagnosed with peripheral T-cell lymphoma or natural killer cell neoplasms
Available fresh tumor samples from patients treated on ECOG-E2404 and normal DNA (non-ECOG) samples
PATIENT CHARACTERISTICS:
Not specified
PRIOR CONCURRENT THERAPY:
See Disease Characteristics
Clareo Health | Biomarkers in Tumor Tissue Samples From Patients With Peripheral T-cell Lymphoma or Natural Killer Cell Neoplasms
